No Intervention for this observational study
OtherNo Intervention for this observational study
NCT Number: NCT05050669
The purpose of this prospective study is to characterize the natural history of ENPP1 Deficiency and the early-onset form of ABCC6 Deficiency longitudinally. The study will prospectively gather information about the biochemical, physiological, anatomic, radiographic, and functional manifestations (including patient reported outcomes) of each disease.
Looking for future studies?
Notify Me2 year–18 year
All sexes
Observational
CHU Sainte-Justine, Montreal, Quebec, Canada
Study INZ701-003 is a multicenter, prospective, longitudinal, observational study to evaluate disease presentation, progression, and burden of illness in pediatric subjects aged 2 to <18 years with ENPP1 Deficiency and the early-onset form of ABCC6 Deficiency. Subjects will receive care available at the clinical site along with additional assessments administered by the study team.
To participate in this study, subjects will give informed assent and parents/guardians will provide informed consent.
Subject participation will consist of a Screening Period and an Observation Period.
Assessments will be performed at each visit as indicated in the Schedule of Events.
During the Screening Period, assessments will be performed to determine eligibility.
Screening and Baseline assessments may be conducted on the same day if the Investigator determines that the patient can successfully complete all study procedures in one day due to their age. If not, sites may schedule additional visits, as needed. A subject will be enrolled into the study if they meet all eligibility criteria.
During the Observation Period, subjects will be assessed for changes in their disease in the following areas: measurements of physiological function (including laboratory testing and anatomical and radiographical assessment of calcification and bone mineralization); performance outcomes; patient, caregiver, and physician reported outcomes; and healthcare utilization.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Individuals eligible to participate must meet all of the following inclusion criteria:
Exclusion criteria
Individuals who meet the following exclusion criterion will not be eligible to participate:
No Intervention for this observational study
Time frame: Up to 12 months
For each subject, blood plasma will be assayed for Plasma Inorganic Pyrophosphate (PPi), comparing the subjects baseline value over time
Time frame: Up to 12 months
For each subject, occurrence of arterial calcification will be examined
Time frame: Up to 12 months
For each subject, occurrence of organ calcification will be examined
Time frame: Up to 12 months
For each subject, skeletal radiographs will be obtained to determine skeletal abnormalities and will be compared to baseline
Time frame: Up to 12 months
For each subject, aged 4 to <18 years, range of motion will be assessed comparing to subjects baseline over time
Inozyme Pharma
Industry
A Prospective Observational Study to Evaluate Disease Presentation and Progression in Subjects With ENPP1 Deficiency and the Early-Onset Form of ABCC6 Deficiency
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04686175
Arterial calcification of infancy, Autosomal Recessive Hypophosphatemic Rickets
Rochester, Minnesota, United States
View Trial DetailsNCT05734196
ATP-Binding Cassette Subfamily C Member 6 Deficiency, Arterial calcification of infancy
San Diego, California, United States
View Trial DetailsNCT06046820
Arterial calcification of infancy, Autosomal Recessive Hypophosphatemic Rickets
Aurora, Colorado, United States
View Trial DetailsNCT07473973
Arterial calcification of infancy, Autosomal Recessive Hypophosphatemic Rickets
Rio de Janeiro, Brazil
View Trial Details